NTRK Fusion Gene Positive Advanced Solid Tumor Market - Top Companies and Manufacturers

In the News

• The National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has granted Breakthrough Therapy Designation for investigational repotrectinib for the treatment of patients with advanced solid tumors with an NTRK gene fusion that has progressed after treatment with TRK tyrosine kinase inhibitors (TKIs). Repotrectinib was designated as a Breakthrough Therapy, based on findings from patients in the Phase 1/2 TRIDENT-1 study who were TKI-pretreated and NTRK-positive, both international and Chinese.
• Pyramid Biosciences, Inc. reports that PBI-200 has been designated as an orphan medication by the FDA for the treatment of patients with NTRK fusion-positive solid tumors, including primary and metastatic brain tumors. PBI-200 is a next-generation inhibitor that is being developed clinically for patients with tropomyosin receptor kinase (TRK) disorders. It is an oral medication that is highly powerful and selective. The inhibitor is made to counteract a variety of on-target resistance mutations that have been observed with first-generation TRK inhibitors in the past.